AskBio Launches AskFirst Advocacy Program to Educate and Support Gene Therapy Trial Participants

AskBio Launches AskFirst Advocacy Program to Educate and Support Gene Therapy Trial Participants
0
(0)

Asklepios Biopharmaceutical (AskBio) has introduced a collaborative program designed to educate patients who may benefit from gene therapy, and to support those in clinical trials.

Called AskFirst, the program is intended to keep patients and families apprised of the company’s gene therapy research and potential cures for diseases such as Pompe.

Pompe is caused by mutations in the GAA gene, which provides instructions for an enzyme called alpha-glucosidase that is involved in breaking down glycogen. AskBio is using its adeno-associated virus technology platform to develop a gene therapy for Pompe, aimed at restoring the body’s ability to produce functional acid alpha-glucosidase enzyme on its own by providing cells with a functioning copy of the GAA gene.

In addition to supporting clinical trial participants, another AskFirst goal is to ensure accurate communication of the clinical-stage gene therapy company’s product safety information.

“AskBio was founded with a patient-focused mission to develop transformative genetic medicines for patients with serious diseases previously considered untreatable,” said Martin Childers, PhD, AskBio’s chief medical officer, in a press release.

“This patient-centered approach is at the heart of our AskFirst program that embraces the voice of patients and their families that puts their welfare first. We support the important work of patient advocacy organizations that play an essential role in advancing gene therapy.”

The effort will include patients and families in clinical study design, and bring together scientists, technicians, and clinical specialists who will engage patients during therapy development. In addition, AskFirst will create study protocols to ultimately speed novel treatment delivery, build sustainable relationships with advocacy organizations, and engage patient advocacy liaisons who have direct access to research teams to get answers when needed.

To lead AskFirst, AskBio has hired Matthew Alsante to direct patient advocacy. Alsante has more than a decade of experience with patient advocacy organizations, having served as former executive director of the Sarcoma Foundation of America and, most recently, as the CEO of the National Pancreas Foundation.

“AskBio has a long history of commitment to the patient community, and I’m honored to build upon that foundation and provide an external link to the important life-changing work that is happening here,” he said. “The patient voice is vital to everything we do. It’s my job to bring that into every aspect of gene therapy development, because we can’t do it without the incredible partnerships we have with patients and the community.”

Mary M. Chapman began her professional career at United Press International, running both print and broadcast desks. She then became a Michigan correspondent for what is now Bloomberg BNA, where she mainly covered the automotive industry plus legal, tax and regulatory issues. A member of the Automotive Press Association and one of a relatively small number of women on the car beat, Chapman has discussed the automotive industry multiple times of National Public Radio, and in 2014 was selected as an honorary judge at the prestigious Cobble Beach Concours d’Elegance. She has written for numerous national outlets including Time, People, Al-Jazeera America, Fortune, Daily Beast, MSN.com, Newsweek, The Detroit News and Detroit Free Press. The winner of the Society of Professional Journalists award for outstanding reporting, Chapman has had dozens of articles in The New York Times, including two on the coveted front page. She has completed a manuscript about centenarian car enthusiast Margaret Dunning, titled “Belle of the Concours.”
Total Posts: 3
Margarida graduated with a BS in Health Sciences from the University of Lisbon and a MSc in Biotechnology from Instituto Superior Técnico (IST-UL). She worked as a molecular biologist research associate at a Cambridge UK-based biotech company that discovers and develops therapeutic, fully human monoclonal antibodies.
×
Mary M. Chapman began her professional career at United Press International, running both print and broadcast desks. She then became a Michigan correspondent for what is now Bloomberg BNA, where she mainly covered the automotive industry plus legal, tax and regulatory issues. A member of the Automotive Press Association and one of a relatively small number of women on the car beat, Chapman has discussed the automotive industry multiple times of National Public Radio, and in 2014 was selected as an honorary judge at the prestigious Cobble Beach Concours d’Elegance. She has written for numerous national outlets including Time, People, Al-Jazeera America, Fortune, Daily Beast, MSN.com, Newsweek, The Detroit News and Detroit Free Press. The winner of the Society of Professional Journalists award for outstanding reporting, Chapman has had dozens of articles in The New York Times, including two on the coveted front page. She has completed a manuscript about centenarian car enthusiast Margaret Dunning, titled “Belle of the Concours.”
Latest Posts
  • exercise and Pompe disease
  • mindfulness
  • genetic counseling
  • Covid-19 survey

How useful was this post?

Click on a star to rate it!

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this post.

As you found this post useful...

Follow us on social media!

We are sorry that this post was not useful for you!

Let us improve this post!

Tell us how we can improve this post?